Jing Li1, Haiyi Lou1, Xiong Yang1, Dongsheng Lu1, Shilin Li2, Li Jin2, Xinwei Pan2, Wenjun Yang3, Manshu Song4, Dolikun Mamatyusupu5, Shuhua Xu1. 1. Max Planck Independent Research Group on Population Genomics, Chinese Academy of Sciences and Max Planck Society (CAS-MPG) Partner Institute for Computational Biology (PICB), Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China. 2. State Key Laboratory of Genetic Engineering and Ministry of Education (MOE) Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, China. 3. Key Laboratory of Reproduction and Heredity of Ningxia Region, Ningxia Medical University, Yinchuan, Ningxia, China. 4. School of Public Health, Capital Medical University and Municipal Key Laboratory of Clinical Epidemiology, Beijing, China. 5. College of the Life Sciences and Technology, Xinjiang University, Urumqi, China.
Abstract
BACKGROUND: Drug absorption, distribution, metabolism and excretion (ADME) contribute to the high heterogeneity of drug responses in humans. However, the same standard for drug dosage has been applied to all populations in China although genetic differences in ADME genes are expected to exist in different ethnic groups. In particular, the ethnic minorities in northwestern China with substantial ancestry contribution from Western Eurasian people might violate such a single unified standard. METHODS: In this study, we used Affymetrix SNP Array 6.0 to investigate the genetic diversity of 282 ADME genes in five northwestern Chinese minority populations, namely, Tajik, Uyghur, Kazakh, Kirgiz and Hui, and attempted to identify the highly differential SNPs and haplotypes and further explore their clinical implications. RESULTS: We found that genetic diversity of many ADME genes in the five minority groups was substantially different from those in the Han Chinese population. For instance, we identified 10 functional SNPs with substantial allele frequency differences, 14 functional SNPs with highly different heterozygous states and eight genes with significant haplotype differences between these admixed minority populations and the Han Chinese population. We further confirmed that these differences mainly resulted from the European gene flow, that is, this gene flow increased the genetic diversity in the admixed populations. CONCLUSIONS: These results suggest that the ADME genes vary substantially among different Chinese ethnic groups. We suggest it could cause potential clinical risk if the same dosage of substances (eg, antitumour drugs) is used without considering population stratification. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
BACKGROUND: Drug absorption, distribution, metabolism and excretion (ADME) contribute to the high heterogeneity of drug responses in humans. However, the same standard for drug dosage has been applied to all populations in China although genetic differences in ADME genes are expected to exist in different ethnic groups. In particular, the ethnic minorities in northwestern China with substantial ancestry contribution from Western Eurasian people might violate such a single unified standard. METHODS: In this study, we used Affymetrix SNP Array 6.0 to investigate the genetic diversity of 282 ADME genes in five northwestern Chinese minority populations, namely, Tajik, Uyghur, Kazakh, Kirgiz and Hui, and attempted to identify the highly differential SNPs and haplotypes and further explore their clinical implications. RESULTS: We found that genetic diversity of many ADME genes in the five minority groups was substantially different from those in the Han Chinese population. For instance, we identified 10 functional SNPs with substantial allele frequency differences, 14 functional SNPs with highly different heterozygous states and eight genes with significant haplotype differences between these admixed minority populations and the Han Chinese population. We further confirmed that these differences mainly resulted from the European gene flow, that is, this gene flow increased the genetic diversity in the admixed populations. CONCLUSIONS: These results suggest that the ADME genes vary substantially among different Chinese ethnic groups. We suggest it could cause potential clinical risk if the same dosage of substances (eg, antitumour drugs) is used without considering population stratification. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: J N Liu; M Dolikun; J Štambuk; I Trbojević-Akmačić; J Zhang; H Wang; D Q Zheng; X Y Zhang; H L Peng; Z Y Zhao; D Liu; Y Sun; Q Sun; Q H Li; J X Zhang; M Sun; W J Cao; A Momčilović; G Razdorov; L J Wu; A Russell; Y X Wang; M S Song; G Lauc; W Wang Journal: J Hum Hypertens Date: 2018-06-05 Impact factor: 3.012
Authors: Maulana Bachtiar; Brandon Nick Sern Ooi; Jingbo Wang; Yu Jin; Tin Wee Tan; Samuel S Chong; Caroline G L Lee Journal: Pharmacogenomics J Date: 2019-10-03 Impact factor: 3.550
Authors: Juliana Carla Gomes Rodrigues; Tatiane Piedade de Souza; Lucas Favacho Pastana; André Maurício Ribeiro Dos Santos; Marianne Rodrigues Fernandes; Pablo Pinto; Alayde Vieira Wanderley; Sandro José de Souza; José Eduardo Kroll; Adenilson Leão Pereira; Leandro Magalhães; Laís Reis das Mercês; Amanda Ferreira Vidal; Tatiana Vinasco-Sandoval; Giovanna Chaves Cavalcante; João Farias Guerreiro; Paulo Pimentel de Assumpção; Ândrea Ribeiro-Dos-Santos; Sidney Santos; Ney Pereira Carneiro Dos Santos Journal: PLoS One Date: 2020-04-15 Impact factor: 3.240